Skip to content

FDA advisory committee rejects MDMA application for PTSD, but…

Alison Knopf

Alcoholism & Drug Abuse Weekly June 10, 2024 DOI: 10.1002/adaw.34151 (opens in new tab)

Relevant Not relevant

Study at a glance

AI-extracted from the abstract
Characteristics Peer reviewed
Topics MDMA PTSD
Key points The FDA voted 9-2 to reject the application for MDMA to treat PTSD.

Abstract

Last week, the Food and Drug Administration (FDA) voted 9‐2 to reject the application of Lykos Therapeutics, the newly formed commercial arm of MAPS, for “midomafetamine” (actually MDMA, or methylenedioxymethamphetamine) to treat post‐traumatic stress disorder (PTSD).

Related reading